Mirum Pharmaceuticals Inc (MIRM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.98B
Last updated: Nov 17, 2026 at 4:10 PM ET
Mirum Pharmaceuticals Inc (MIRM) Statistics
Mirum Pharmaceuticals (MIRM) has a market cap of $5.98B and an enterprise value of $6.47B. Its share count is up 29.40% from a year earlier. It kept -134.75% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 8.16% above the market cap, as debt exceeds cash.
| Market Cap | $5.98B |
|---|---|
| Enterprise Value | $6.47B |
| Latest price (Nov 17, 2026) | $91.95 |
Key Dates
| Last Earnings Date | Nov 3, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 9.0x. Its year-end P/S ranged from 5.8x to 25.3x from 2021 to 2025.
| P/S Ratio | 9.0x |
|---|---|
| Forward P/S | 8.3x |
Price Statistics
The stock is up 28.71% over 52 weeks and trades 3.96% above its 50-day average.
| Beta (1Y) | 1.08 |
|---|---|
| 52-Week Change | +28.71% |
| 1-Month Change | +11.81% |
| 3-Month Change | -10.06% |
| 6-Month Change | -3.87% |
| 5-Year Change | +435.26% |
| Total Return (1Y) | +28.71% |
| Total Return (3Y CAGR) | +41.69% |
| Total Return (5Y CAGR) | +42.72% |
| Return vs SPY (1Y) | +15.81% |
| Max Drawdown (1Y) | -38.36% |
| Max Drawdown (3Y) | -38.36% |
| Sharpe Ratio (1Y) | 0.50 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $88.45 |
| 200-Day Average | $98.29 |
| 52-Week Range | $63.23 to $130.00 |
| RSI (14 Days) | 54.9 |
| Average Volume (20 Days) | 601.41K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.07x current liabilities.
| Current Ratio | 2.07x |
|---|---|
| Quick Ratio | 1.98x |
| Interest Coverage | -79.06x |
Returns and Efficiency
Return on invested capital is -133.57% over the last 12 months, against a 5-year average of -3.16%.
| Return on Assets (ROA) | -88.04% |
|---|---|
| Return on Invested Capital (ROIC) | -133.57% |
| ROE (5Y Average) | -55.50% |
| ROA (5Y Average) | -21.62% |
| ROIC (5Y Average) | -3.16% |
| Asset Turnover | 0.74x |
| Inventory Turnover | 4.78x |
| Receivables Turnover | 4.45x |
| Cash Conversion Cycle | 103 days |
Scores
MIRM has an Altman Z-Score of -0.69, in the distress zone below 1.81, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.69 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $670.78M over the last 12 months is up 42.18% from the 12 months before.
| Revenue | $670.78M |
|---|---|
| Revenue Growth (YoY) | +42.18% |
| Gross Profit | $548.19M |
| Operating Income | -$896.32M |
| Pretax Income | -$900.41M |
| Net Income | -$903.88M |
| EBITDA | -$875.16M |
| Reported EPS (TTM) | -$2.87 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $243.19M |
|---|---|
| Total Debt | $731.25M |
| Net Debt | $488.06M |
| Net Debt Per Share | $7.45 |
| Working Capital | $303.55M |
| Shareholder Equity | -$54.19M |
| Tangible Book Value | -$329.83M |
| Total Assets | $1.03B |
| Total Liabilities | $1.08B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $2.59M of capital spending, operating cash flow left -$273.85M of free cash flow.
| Operating Cash Flow | -$271.26M |
|---|---|
| Capital Expenditures | $2.59M |
| Free Cash Flow | -$273.85M |
| FCF Per Share | -$4.22 |
| Depreciation and Amortization | $29.17M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -133.62%.
| Gross Margin | 81.72% |
|---|---|
| Operating Margin | -133.62% |
| Pretax Margin | -134.23% |
| Net Margin | -134.75% |
| EBITDA Margin | -130.47% |
| FCF Margin | -40.83% |
| Gross Margin (5Y Average) | 83.05% |
Growth
Revenue grew 89.13% a year over 3 years.
| Revenue Growth (3Y CAGR) | +89.13% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | +8.53% |
Dividends and Yields
MIRM does not pay a dividend. Its free cash flow yield is -4.55%.
| FCF Yield | -4.55% |
|---|---|
| Buyback Yield | -4.98% |
| Shareholder Yield | -4.98% |
Peer Position
Against 7 similar companies, MIRM has the 4th highest P/S.
P/S RatioPeer median 8.6x
ROICPeer median -26.18%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +31.82%
| P/S Ratio | 9.0x vs 8.6x median |
|---|---|
| ROIC | -133.57% vs -26.18% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +42.18% vs +31.82% median |
Analyst Forecast
Consensus estimates put revenue growth at 29.08% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +29.08% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About MIRM
What is MIRM's market cap?
Mirum Pharmaceuticals has a market cap of $5.98B. Its enterprise value, which adds debt and subtracts cash, is $6.47B.
How many shares of MIRM are outstanding?
Mirum Pharmaceuticals has 65.53M shares outstanding. The count is up 29.40% from a year earlier.
Does MIRM pay a dividend?
No. Mirum Pharmaceuticals does not pay a dividend.
How much debt does MIRM have?
Mirum Pharmaceuticals has $731.25M of total debt and $243.19M of cash and equivalents, a net debt position of $488.06M.
MIRM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors, Government Contracts